Kappa Bioscience & S.A. Pharmachem Pvt. Ltd. to Focus CPHI19 on Vitamin K2 Pharma Success Since Drug Approval

Kappa’s microencapsulated K2VITAL® DELTA K2-7 product was granted registration and a drug import license. This enabled the expansion of vitamin K2 into the Indian pharmaceutical market and opened new channels to consumers. Osteoporosis is a significant problem within India’s large and growing elderly population, and calcium supplementation is a common prescription. Pharmaceutically approved vitamin K2 ensures that calcium supplementation optimally supports bone health, but does not interfere with healthy cardiovascular function.

Kappa’s microencapsulated K2VITAL® DELTA K2-7 product was granted registration and a drug import license. This enabled the expansion of vitamin K2 into the Indian pharmaceutical market and opened new channels to consumers. Osteoporosis is a significant problem within India’s large and growing elderly population, and calcium supplementation is a common prescription. Pharmaceutically approved vitamin K2 ensures that calcium supplementation optimally supports bone health, but does not interfere with healthy cardiovascular function.

CPHI19 will mark the Asian release of Kappa’s new 9-year study on vitamin K2 product quality. Unprotected vitamin K2 is not stable in formulations with mineral salts such as calcium or magnesium. Kappa’s Market Study 2019 spans 409 global K2 products and demonstrates that 84% of K2+minerals products failed label claim for K2 amount. These results mirror Kappa’s findings for Indian products published in 2018. Kappa’s protected, microencapsulated K2VITAL® DELTA is the market-leading solution for K2 stability. DELTA® is the only microencapsulated K2 with Indian drug approval.

Kappa and S.A. Pharmachem will present recent market developments such as the newly developed Critical Quad model. The model describes why the time is right for brands and manufacturers to launch successful K2 products. The new 2019 edition of the K2 Formulation LookBook will also be distributed at CPHI. The LookBook is a complete source of information on how to launch K2 products, including 150 formulations which are available for license-free use. Kappa will also present several new sample concepts tailored to Indian consumers. DELTA’s proven stability with calcium reduces overage, delivers better cost-per-use than unprotected K2, and ensures K2 label claim.